Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and healthcare products.

It is set to report its Q4 2025 earnings on Feb. 3. Wall Street analysts expect the company to post EPS of $0.61, down from $0.63 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $17.67 billion, down from $17.76 billion a year earlier.

Don’t Miss:

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy’ — Investors Can Still Get In at $0.85/Share

• Earn While You Scroll: The Deloitte-Ranked #1 Software Company Growing 32,481% Is Opening Its $0.50/Share Round to Accredited Investors.

The company’s stock traded at approximately $31.11 per share 10 years ago. If you had invested $10,000, you could have bought roughly 321 shares. Currently, shares trade at $25.71, meaning your investment’s value could have declined to $8,264 from stock price depreciation. However, Pfizer also paid dividends during these 10 years.

Pfizer’s dividend yield is currently 6.69%. Over the last 10 years, it has paid about $15.70 in dividends per share, which means you could have made $5,047 from dividends alone.

Summing up $8,264 and $5,047, we end up with the final value of your investment, which is $13,311. This is how much you could have made if you had invested $10,000 in Pfizer stock 10 years ago. This means a total return of 33.11%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 287.90%.

Trending: An EA Co-Founder Shapes This VC Backed Marketplace—Now You Can Invest in Gaming’s Next Big Platform

Pfizer has a consensus rating of “Neutral” and a price target of $33.35 based on the ratings of 24 analysts. The price target implies more than 29% potential upside from the current stock price.

The company on Nov. 4 announced its Q3 2025 earnings, posting adjusted EPS of $0.87, compared to the consensus estimate of $0.63, and revenues of $16.65 billion, compared to the consensus of $16.59 billion, as reported by Benzinga.

Pfizer raised its full-year 2025 adjusted EPS guidance to the range of $3 to $3.15, versus consensus estimate of $3.04. The U.S. drug giant reaffirmed its full-year revenue guidance of $61 billion to $64 billion, compared to the consensus of $62.88 billion.